Is CD20 positive plasma cell myeloma a unique clinicopathological entity? A study of 40 cases and review of the literature

Pathology

Volumn 44, Issue 6, 2012, Pages 552-556

  Grigoriadis, George ^a,b   Gilbertson, Michael ^a   Came, Neil ^a,c,d   Westerman, David ^c,d   Fellepa, Frank ^a   Jene, Nick ^c   Chapple, Peter ^a   Juneja, Surender ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CD20 antigen; Immunohistochemistry; Myeloma

Indexed keywords

EID: 84866901531     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283583f5d     Document Type: Article

References (31)

1. Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102: 1070-1.
2. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, et al. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 1987; 87: 341-55.
3. Heerema-McKenney A, Waldron J, Hughes S, et al. Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma. A potential mimic of mature B-cell lymphoma. Am J Clin Pathol 2010; 133: 265-70.
4. Quinn J, Percy L, Glassford J, et al. CD20-positive multiple myeloma - differential expression of cyclins D1 and D2 suggests a heterogeneous disease. Br J Haematol 2009; 149: 156-9.
5. Lin P, Mahdavy M, Zhan F, et al. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol 2004; 17: 1217-22.
6. Morgan TK, Zhao S, Chang KL, et al. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease. An immunohistochemical analysis. Am J Clin Pathol 2006; 126: 545-51.
7. Cook J, His ED, Worley S, et al. Immunohistochemical analysis identifies two cyclin D1 subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol 2006; 125: 615-24.
8. Kapoor P, Greipp PT, Morice WG, et al. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 2008; 141: 135-48.
9. Baz R, Fanning S, Kunkel L, et al. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leuk Lymphoma 2007; 48: 2338-44.
10. Bergua JM, Cabrera C, Arterta EG, et al. Rituximab in CD20 positive multiple myeloma. Leukemia 2008; 22: 1082-3.
11. Greipp PT, Kapoor P, Morice WG, et al. Reply to 'rituximab in CD20 positive positive multiple myeloma' by P Moreau et al. Leukemia 2008; 22: 215-6.
12. Ohno H. Long-term response to maintenance treatment with rituximab in CD20 multiple myeloma. Leuk Lymphoma 2010; 5: 2144-6.
13. Moreau P, Voillat L, Benboukher L, et al. IFM groupRituximab in CD20 positive multiple myeloma. Leukemia 2007; 4: 835-6.
14. McKenna RW, Kyle RA, Kuehl WM, et al. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organisation Classification of Tumours of Haemopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press, 2008; 200-13.
15. Goasguen JE, Zandecki M, Mathiot C, et al. Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res 1999; 23: 1133-40.
16. Ng AP,Wei A, Bhurani D, et al. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica 2006; 91: 972-5.
17. Walters M, Olteanu H, Tuinen PV, et al. CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary cell leukaemia in this cytogenetic group. Br J Haematol 2010; 149: 292-4.
18. Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005; 11: 3661-7.
19. Ngo NT, Brodie C, Giles C, et al. The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome. J Clin Pathol 2009; 62: 1009-15.
20. Moreau P, Facon T, Leleu X, et al. Intergroupe Francophone du Mye'lome. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579-83.
21. San Miguel F, Gonzalez M, Gascon A, et al. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of disease. Br J Haematol 1991; 77: 185-90.
22. Caers J, Vande broek I, De Raeve H, et al. Multiple myeloma - an update on diagnosis and treatment. Eur J Haematol 2008; 81: 329-43.
23. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
24. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-20.
25. FaliniB, Fizzotti M, PucciariniA, et al.Amonoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-92.
26. Heintel D, Zojer N, Schreder M, et al. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia 2008; 22: 441-5.
27. Hagman J, Wheat W, Fitzsimmons D, et al. Pax-5/BSAP: regulator of specific gene expression and differentiation in B lymphocytes. Curr Top Microbiol Immunol 2000; 245: 169-94.
28. Hibbert RG, Teriete P, Grundy GJ, et al. The structure of human CD23 and its interactions with IgE and CD21. J Exp Med 2005; 202: 751-60.
29. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001; 20: 5611-22.
30. Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303.
31. Fisher CJ, Gillett CE, Vojtesek B, et al. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 1994; 69: 26-31.